Fig. 4From: The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimabA Progression-free survival and B overall survival in patients with type 2 diabetes with increasing or stable blood glucose level during immunotherapy. Increasing level of glucose on treatment was defined as the ratio of blood level at baseline/after 3 months > 1.5Back to article page